Revvity, Inc., announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions.
This initiative builds upon Revvity's recent introduction of an automated next-generation sequencing (NGS) workflow for newborn sequencing research and strengthens Element’s momentum toward regulatory approval of the benchtop AVITI sequencing system.
The collaboration involves the co-development of a comprehensive IVD solution tailored for newborn sequencing. Additionally, customers will have immediate access to a research use only (RUO) version of the newborn sequencing research workflow.
The new IVD solution powered by Revvity will be an important organic next step for each company, expanding the reach of both Element’s AVITI sequencing system and Revvity's newborn sequencing research workflow, which includes its sample collection devices, dried blood spot punchers, automated nucleic acid extractors, liquid handers, NGS library preparation kits with carefully curated NGS panels, and comprehensive software for variant calling data analysis and interpretation. The combined technologies will provide an end-to-end solution for the NGS continuum that supports pioneering neonatal research and the necessary approvals for a cutting-edge IVD in this field.